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Background Triple therapy combining a protease inhibitor (PI) telaprevir or boceprevir, 33 
pegylated-interferon (Peg-IFN) and ribavirin (RBV) have dramatically increased the chance 34 
to eradicate hepatitis C virus (HCV). However the efficacy of this treatment remains 35 
suboptimal in cirrhotic experienced-patients. Here we aimed to better understand the origin of 36 
this impaired response by estimating the antiviral effectiveness of each drug.  37 
Methods Fifteen genotype 1-patients with compensated cirrhosis, non-responders to a prior 38 
Peg-IFN/RBV therapy were enrolled in a non-randomized study. HCV-RNA and drug 39 
concentrations of PIs, Peg-IFN and RBV were frequently assessed in the first 12 weeks of 40 
treatment and were analyzed using a pharmacokinetics/viral kinetics model.  41 
Results Both PIs achieved similar level of molar concentrations (P=0.5), but there was a 42 
significant difference of EC50 (P=0.008), leading to a larger antiviral effectiveness than 43 
boceprevir in blocking viral production (99.8% vs 99.0%, respectively, P=0.002). In all 44 
patients the antiviral effectiveness of Peg-IFN was modest (43.4%) and there was no 45 
significant contribution of RBV exposure on the total antiviral effectiveness. The second 46 




) and was higher in patients that subsequently eradicated HCV (P=0.03).  48 
Conclusion Both PIs achieved a high level of antiviral effectiveness. However the suboptimal 49 
antiviral effectiveness of Peg-IFN/RBV and the low loss of infected cells suggest that longer 50 
treatment duration might be needed in cirrhotic treatment experienced-patients and that future 51 
IFN-free regimen may be particularly beneficial to these patients. 52 
 53 
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Introduction  57 
Chronic infection with hepatitis C virus (HCV) affects approximately 160 million people 58 
worldwide (1) and is the leading cause of cirrhosis, liver cancer and liver transplantation (2). 59 
The goal of treatment is to achieve a sustained virological response (SVR), marker of viral 60 
eradication, assessed by the absence of detectable HCV RNA six months after treatment 61 
discontinuation. The approval in 2011 of two protease inhibitors (PI), telaprevir and 62 
boceprevir, in combination with pegylated-interferon-alpha and ribavirin (Peg-IFN/RBV) (3), 63 
has marked an important milestone with SVR rates higher than 70% in HCV genotype 1 64 
infected patients (4, 5). Recently two new triple therapy involving sofosbuvir, a nucleoside 65 
polymerase inhibitor, and simeprevir, a new protease inhibitor, have been approved by the 66 
European and American regulatory agencies, showing in clinical trials even higher SVR rates 67 
of 90% (6). However the cost of these new treatments, about twice as much as telaprevir or 68 
boceprevir-based therapy (7), will make them out of reach for many countries. Therefore 69 
triple therapy with Peg-IFN, RBV and telaprevir/boceprevir will continue to be vastly used in 70 
the next years and will remain the only therapeutic option for many patients. 71 
Although these results suggest that a functional cure might be obtained in a large majority of 72 
patients, one should keep in mind that issues remain. In particular the proportion of patients 73 
with advanced liver disease and cirrhosis and/or who had failed a previous treatment with 74 
Peg-IFN/RBV is under represented in the patient population in clinical trials (8–11). The 75 
evaluation of the triple therapy in this population was precisely the goal of the ANRS-CO20-76 
CUPIC cohort (Compassionate Use of Protease Inhibitors in viral C Cirrhosis; 77 
ClinicalTrials.gov number: NCT01514890) (12), where 511 genotype 1 treatment-78 
experienced cirrhotic patients were included. In this study the SVR rates 12 weeks after 79 
treatment discontinuation (SVR12) were equal to 52% and 43% in telaprevir and boceprevir 80 
treated patients, respectively (13). The origin of this impaired response might encompass a 81 
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variety of factors, in particular impaired drug pharmacokinetics (PK) or limited sensitivity to 82 
PI agents and/or Peg-IFN/RBV in this particular population. 83 
One way to evaluate treatment antiviral effectiveness and to optimize therapy is to use PK- 84 
viral kinetic (VK) models that provide a useful tool to quantitatively describe the relationship 85 
between drug exposure and viral response (reviewed in (14)). However no such analysis has 86 
been published with boceprevir and results published for telaprevir were mostly based on 87 
treatment naive and/or non-cirrhotic patients (15–17). 88 
Here, we aimed to get new insights into the determinants of the response to triple therapy by 89 
analyzing in details, within a subset of 15 patients enrolled in the ANRS-CO20-CUPIC study, 90 
the relationship between drug concentrations and early virological response. We used the 91 
techniques of PK-VK modeling in order to tease out the relative antiviral effectiveness of 92 
each of the agents involved in the triple therapy (i.e., boceprevir or telaprevir, Peg-IFN and 93 




Materials and methods 96 
Patients and data 97 
MODCUPIC is a substudy of the French multicentre prospective ANRS-CO20-CUPIC 98 
cohort. In four centres, from September 2011 to September 2012, patients chronically 99 
monoinfected with HCV genotype 1, compensated cirrhosis (Child-Pugh class A), non-100 
responders to a prior IFN-based therapy and who started triple therapy were recruited. The 101 
diagnosis of cirrhosis was made by liver biopsy or non-invasive tests, Fibrotest® or 102 
Fibroscan® or Fibrometer® or Hepascore® at the discretion of the investigator, according to 103 
the French recommendations (18). The choice between TVR- or BOC-based therapies was at 104 
the investigator’s discretion without randomization. TVR-based therapy included 12 weeks of 105 
telaprevir (750 mg/8 hours) in combination with Peg-IFN-α2a (180 µg/week) and RBV (1,000 106 
or 1,200 mg/day, depending on body weight) then 36 weeks of Peg-IFN-α2a/RBV (named 107 
group telaprevir in the following). BOC-based therapy included 4 weeks (lead-in phase) of 108 
Peg-IFN-α2b (1.5 µg/kg/week) or Peg-IFN-α2a (180 µg/week) and RBV (800 or 1,400 109 
mg/day, depending on body weight) then 44 weeks of Peg-IFN-α2b/RBV and boceprevir (800 110 
mg/8 hours) (named group boceprevir in the following). Patients were followed up to six 111 
months after treatment discontinuation to assess SVR. 112 
Written informed consent was obtained before enrolment. The protocol was conducted in 113 
accordance with the Declaration of Helsinki and was approved by the "Ile-de-France IX 114 
Ethics Committee" (Créteil, France). 115 
 116 
Bioanalytical methods 117 
HCV RNA and drug concentrations were measured post PIs initiation at hours 0, 8, days 1, 2, 118 
3 and weeks 1, 2, 3, 4, 8 and 12. Patients treated with boceprevir had two additional VL and 119 
concentrations measurements during the lead-in phase. Blood samples were collected early in 120 
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the morning before the first daily dose of PIs and RBV and therefore only trough pre-dose 121 
drug concentrations were collected. All samples were collected on SST (serum) vacutainers, 122 
kept at 4°C until centrifuged at 3,000 RPM for 10 minutes in a 4°C centrifuge, within 1 hour 123 
after collection, aliquoted and kept at -80°C until analysis. 124 
PIs concentrations in serum were determined using ultra-performance liquid chromatography 125 
coupled with tandem mass spectrometry with a lower limit of quantification (LOQ) of 5 ng/ml 126 
and 10 ng/ml for boceprevir and telaprevir, respectively (19). PI concentrations were 127 
converted to µmol/l for analysis using molar masses of 519.68 g/mol and 679.85 g/mol for 128 
boceprevir and telaprevir, respectively. RBV concentrations in serum were determined using 129 
ultra-performance liquid chromatography coupled with UV detection with a LOQ of 100 130 
ng/ml (20). Peg-IFN-α2a and -α2b in serum were determined with a bioassay which was 131 
chosen because the objective was to quantify the antiviral activity of Peg-IFN-α and not only 132 
the concentration. Immunoassay measures the physical quantity of material but does not 133 
differentiate between active and inactive molecules while bioassay for IFN-α is based on the 134 
protection of cultured cells against the cytopathic effect of a challenge virus and also was 135 
suitable for assaying both Peg–IFN-α-2a and Peg–IFN-α-2b. The reference solutions 136 
contained 2.8–180 ng/ml of Peg-IFN-α2a (Roche Diagnostics, Germany) (21). 137 
HCV-RNA levels were measured with a real-time PCR-based assay, Cobas® 138 
Ampliprep/Cobas TaqMan® assay (Roche Diagnostics, Germany), with a lower limit of 139 
detection (LOD) of 15 IU/ml. DNA samples were genotyped for the IL28B rs12979860 140 
polymorphism (AmpliTaq gold® DNA polymerase and BigDye® terminator cycle 141 
sequencing kit, Applied Biosystems, UK). 142 
 143 
Drug pharmacokinetic modeling 144 
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All drug concentrations were fitted separately in telaprevir and boceprevir treatment groups. 145 





respectively were fitted using an exponential model to reflect the progressive increase in 147 
trough drug concentrations over time:         148 
   ܥܲ݁݃െܫܨܰሺݐሻ ൌ ܥݏܲ݁ݏ ݃െܫܨܰ ൈ ሺͳ െ ݁െ݇ݐሻ    Eq. (1) 149 
   ܥܴܤܸሺݐሻ ൌ ܥݏܴݏܤܸ ൈ ሺͳ െ ݁െ݇ݐሻ     Eq. (2) 150 
where Css is the trough concentration at steady state and k the rate constant of elimination 151 
which reflects the progressive increase in C(t) over time.  152 
For both PI drugs, consistent with the fact that they have a short elimination half-life (22), no 153 
significant increase of trough concentrations over time was observed. Therefore 154 
concentrations for both telaprevir and boceprevir were fitted using a constant model, where 155 
Css is the trough concentration:  156 
   ܥܲܫሺݐሻ ൌ ܥݏܲݏܫ       Eq. (3) 157 
 158 
Viral kinetic modeling 159 
The following model of HCV viral kinetics (VK) was used to fit the changes in HCV RNA 160 
(23): 161 
 
ௗூௗ௧ ൌ ܾܸܶ െ ߜܫ 162 
   
ௗ௏ௗ௧ ൌ ݌൫ͳ െ ߝሺݐሻ൯ܫ െ ܸܿ      Eq. (4) 163 
where T represent the target cells that can be infected by virus, V, with rate b. Infected cells, I, 164 
are lost with rate į and produce p virions per day, which are cleared from serum with rate c. 165 
The target cell level is assumed constant throughout the study period (12 weeks) and remains 166 
at its pre-treatment value T0=cį/pβ. Treatment is assumed to reduce the average rate of viral 167 
production per cell from p to p(1–İ), where İ represents the drug antiviral effectivenesses, i.e., 168 
İ = 0.99 implying the drug is 99% effective in blocking viral production. This model predicts 169 
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that VL will fall in a biphasic manner, with a rapid first phase lasting for a couple of days that 170 
reduce the VL with a magnitude equal to log10(1-İ), followed by a second slower but 171 
persistent second phase of viral decline with rate İį. Therefore a difference between İ = 172 
99.9% and İ = 99.0% corresponds to a 10-fold difference in the viral production under 173 
treatment and will lead to 1-log difference between the two curves of viral decline (24). We 174 




/day, respectively, without loss of 175 
generality (25).  176 
The effectiveness of each drug in blocking viral production was described by an Emax model 177 
assuming a maximum inhibition of 100%:  178 
   ߝ௉ூሺݐሻ ൌ ஼ು಺ሺ௧ሻ஼ು಺ሺ௧ሻାா஼ఱబು಺ 179 





) is the PI (resp. Peg-IFN) concentration at which the PI 181 




(t)) are the individual predictions 182 
(see below) given by the PK models (Eq. 1 and 3).  183 
The combined effect of PIs and Peg-IFN was modeled using a Bliss independent action model 184 
(26) and the total efficacy İ(t) was given by:     185 
   ൫ͳ െ εሺtሻ൯ ൌ ሺͳ െ εPIሺtሻሻሺͳ െ εPୣ୥ିIFNሺtሻሻ  Eq. (6) 186 
Since the effect of RBV on the early virological response is expected to be modest (27–29) 187 
we did not incorporate the effect of RBV into the reference model (Eq. 4-6). In a second step 188 
we tested whether the effectiveness of RBV, also modeled using an Emax model could enhance 189 
the effect in blocking viral production or reduce viral infectivity, as suggested previously (30). 190 
 191 
Data analysis and parameter estimation 192 
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The pharmacokinetics/viral kinetics (PK-VK) model given by Eq. 4-6 can be used only to 193 
characterize the viral kinetics of drug sensitive virus and therefore cannot fit viral rebounds 194 
due to the emergence of drug-resistant virus. Therefore only HCV RNA data until virologic 195 
rebounds (with no indication of lack of compliance) were used to estimate the viral kinetic 196 
parameters. 197 
Parameters V0, c, į, EC50PI and EC50Peg-IFN were estimated using non-linear mixed-effect 198 
models (NLMEM). In this approach, each individual parameter și is comprised of a fixed part 199 
ș, which represents the mean value of the parameter in the population (fixed effects), and a 200 
random part Și chosen from a Gaussian distribution with mean 0 and standard deviation ωi 201 
that accounts for the inter-individual variability. Therefore, for all parameters ߠ௜ ൌ ߠ݁ఎ೔ 202 
where ηi ׽ NሺͲ, ωʹሻ. Both PK data and Log10(HCV RNA) were best described using an 203 
additive residual error with constant variance. 204 
Model parameters were estimated using the Stochastic Approximation Expectation 205 
Minimization (SAEM) algorithm in MONOLIX v4.2 (available at http://www.lixoft.eu). Of 206 
note this approach is based on maximum likelihood estimation which take into account the 207 
information brought by data under the LOD as left-censored data (31, 32).  208 
Model selection was done using the Bayesian information criteria (BIC), a fitting criterion 209 
derived for each model from the computation of likelihood that takes into account the number 210 
of estimated parameters used (the lower the better (33)). Model evaluation was performed 211 
using goodness-of-fit plots, as well as the individual weighted residuals (IWRES) and the 212 
normalized prediction distribution errors (NPDE) over time. 213 
 214 




A Wald test on the PK-VK model parameters (c, į, EC50PI) was used to assess the difference 217 
in population parameters between the two groups. Because we previously showed that this 218 
approach could lead to an inflation of the type I error in case of small sample size (N<20 per 219 
group) (34), a permutation test was performed to confirm statistical significance when the 220 
Wald test was significant at the level of 5%. In brief, 1,000 datasets were simulated by 221 
randomly allocating patients to telaprevir or boceprevir group, maintaining a similar 222 
proportion of patients allocated to each groups than in the original dataset. Then the P-value 223 
of the Wald test was calculated for each simulated data set. Finally the corrected P-value of 224 
the permutation test is equal to the proportion of simulated datasets having a P-value lower 225 
than the one found one the original dataset.  226 
Because the genetic barrier to resistance of PI (i.e., the number of change in amino acids 227 
needed to generate mutants with high level of resistance) depends of HCV subgenotype and 228 
therefore lead to different SVR rate, we also estimated the effect of HCV subgenotype (1a vs 229 
non-1a) on viral kinetic parameters. IL28B polymorphism, which is also associated with 230 
response to IFN-based therapy, was not investigated because all these patients had failed to a 231 
previous bitherapy. 232 
 233 
Prediction and comparison of individual parameters 234 
Individual Empirical Bayesian Estimates (EBE) parameters for both PK and VK were 235 
obtained by computing for each patient the Maximum A Posteriori (MAP) estimate. The 236 
individual antiviral effectiveness at steady state, İss, of each agent was defined by: 237 
   ߝ௦௦௉ூ ൌ ஼ೞೞು಺஼ೞೞು಺ାா஼ఱబು಺ 238 
   ߝ௦௦௉௘௚ିூிே ൌ ஼ೞೞು೐೒ష಺ಷಿ஼ೞೞು೐೒ష಺ಷಿାா஼ఱబು೐೒ష಺ಷಿ     Eq. (7) 239 
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Non-parametric two-sided tests (Wilcoxon test) were used to compare i) individual EBE PK 240 
parameters between patients who received telaprevir vs boceprevir and between patients who 241 
received Peg-IFN-α2a vs -α2b, and ii) individual EBE PK parameters between SVR and non-242 
SVR patients. Because all patients were non-responder to Peg-IFN, the effect of IL28B 243 





Fifteen HCV genotype 1 patients were included 9 receiving telaprevir and 6 receiving 247 
boceprevir. Twelve (80%) were men, with a median [min; max] age of 55 [44; 64] years. 248 
Seven (47%) patients were infected with subgenotype 1a, 2 (22%) in telaprevir group and 5 249 
(83%) in boceprevir group. Prior treatment responses were partial response, null response, 250 
relapse and early discontinuation for adverse events in 2, 5, 6 and 2 patients, respectively. 251 
Only two patients had the most favorable IL28B CC genotype (35). Main characteristics of 252 
the patients are presented in Table 1.  253 
Two patients had a viral breakthrough (at weeks 3 and 8). Eleven patients received Peg-IFN-254 
α2a (8 in telaprevir group and 3 in boceprevir group), 3 patients Peg-IFN-α2b (all in 255 
boceprevir group) and one patient in telaprevir group did not receive any injection of Peg-IFN 256 
(and this patient had a viral breakthrough at week 3).  257 
Fig. 1 shows the observed drug concentrations versus time and Table 2 gives the estimated 258 
steady state trough concentrations, Css, for all drugs. There was no significant difference in 259 
the molar medians steady state concentrations of telaprevir and boceprevir (Css
telaprevir
 = 3.77 260 
[2.68; 5.98] µmol/l i.e. 2,563.0 ng/ml [1,822.0; 4,065.5] and Css
boceprevir
 = 3.92 [3.22; 7.64] 261 
µmol/l i.e. 2037.1 ng/ml [1,673.4; 3,970.4], P=0.5). There was no significant difference in the 262 
median steady state concentrations of Peg-IFN-α2a and -α2b (CssPeg-IFN-2a = 89.6 [52.8; 110.4] 263 
ng/ml and Css
Peg-IFN-2b
 = 55.4 [55.3; 57.9] ng/ml, P=0.2). The concentrations of RBV increased 264 
over time in all patients and could be well captured by our model (Eq. 2) with a median k 265 
equal to 0.10 day
-1
, corresponding to a half-life of increase of about 7 days. At equilibrium 266 
medians Css
RBV
 were equal to 2,860 [2,428; 3,874] ng/ml.  267 
After the PK parameters were estimated, the predicted individual PK time courses were 268 
plugged into the PK-VK model (see methods). Baseline VL was higher in the telaprevir group 269 





 = 6.43 log10 IU/ml vs V0
boceprevir
 = 5.52 log10 IU/ml, P=0.0001). A greater proportion 271 
of patients that received boceprevir were genotype 1a relative to those that received telaprevir 272 
(P=0.04). Subgenotype is an important predictor of the response to treatment, in particular 273 
with telaprevir with a lower genetic barrier to resistance with genotype 1a than 1b (only one 274 
nucleotide change in genotype 1a viral genomes is required to generate mutations V36M and 275 
R155K/T, vs two in genotype 1b) (36). This may explain why genotype 1a patients were 276 
preferentially treated with boceprevir. We did not find any significant effect of subgenotype 277 
on any of the parameters. 278 
The model could well describe the kinetics of HCV decline observed both during the lead-in 279 
phase (in the boceprevir group) and after the initiation of the PIs (in both groups, see Fig. 2). 280 
There was no evidence of model misspecification as showed by the goodness-of-fit plot (Fig. 281 
3) and all parameters could be estimated with a good precision (Table 3). 282 
The model predicted a mean EC50
Peg-IFN
 equal to 106 ng/ml, leading to a low antiviral 283 
effectiveness at steady state of Peg-IFN at steady state of 43.4% [0.0; 52.7], consistent with 284 
the modest 0.67 log10 IU/ml drop observed during the four weeks lead-in phase in patients 285 
treated with boceprevir (Fig. 2). 286 
After PI initiation, VL declines in a biphasic manner in all patients, where a rapid first phase 287 
was followed by a second slower phase. The rapid first phase was attributed to a clearance 288 
rate of virus, c, equal to 3.98 day
-1
 and to a high level of antiviral effectivenesses for both PIs. 289 
The intrinsic potency of the two molecules, as measured by the EC50
PI
, was significantly 290 
higher for telaprevir than boceprevir (EC50
telaprevir
 = 0.009 µmol/l vs EC50
boceprevir
 = 0.04 291 
µmol/l, P=0.008). Importantly the statistical significance of this difference was obtained after 292 
taking into account the small sample size (see methods) and adjusted on baseline VL. Since 293 
telaprevir had a lower EC50 than boceprevir and that both drugs achieved similar levels of 294 
molar concentrations the model predicted that the median individual antiviral effectiveness of 295 
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PI agent in blocking viral production was significantly higher in patients that received 296 
telaprevir than in those who received boceprevir (İsstelaprevir = 99.8% [99.3; 99.9] and İssboceprevir 297 
= 99.0% [98.0; 99.6], P=0.002). Interestingly this model could well capture the relationship 298 
between the serum exposure and its antiviral effectiveness, demonstrating that the variability 299 
in drug exposure needs to be taken into account to understand the between-subject variability 300 
in PIs antiviral effectiveness (Fig. 4A). Lastly because the effectiveness of both PIs were 301 
much larger than that of Peg-IFN (Fig. 4B), the total antiviral effectiveness obtained by the 302 
combination of PI and Peg-IFN was largely similar to the one obtained with the PIs only. 303 
After the VL was rapidly reduced as a result of the strong antiviral effectiveness of both PIs, 304 
the model predicted that a second slower phase of viral decline ensued, driven by the loss rate 305 
of infected cells, į. We estimated į to be equal to 0.18 day-1, corresponding to a half-life of 306 
infected cells of 3.9 days, with no significant differences between patients receiving telaprevir 307 
and boceprevir (P=0.5).  308 
Next we investigated the relationship between the PK-VK parameters and SVR. Among the 7 309 
patients (47%) who achieved SVR, 5 received telaprevir and 2 received boceprevir (56% vs 310 
33%, respectively, P=0.6). As shown in Fig. 5, neither the antiviral effectivenesses of PIs nor 311 
that of Peg-IFN was significantly associated with the long term virological response. However 312 
the loss rate of infected cells, į, was significantly higher in patients that subsequently 313 
achieved SVR (median įSVR = 0.27 day-1 vs median įnon-SVR = 0.14 day-1, P=0.03).  314 
Lastly we verified that incorporating the effect of RBV exposure in the PK-VK model, either 315 
on the block of viral production or in the decrease of viral infectivity (data not shown) did not 316 
improve the fit of the data. Furthermore there was no significant association between the 317 
predicted Css
RBV




Discussion  320 
Here we used a PK-VK model to provide the first detailed picture of the relationship between 321 
the exposure to all drugs involved in triple therapy (Peg-IFN, RBV and telaprevir or 322 
boceprevir) and the early virological response. This novel model provides important insights 323 
into the understanding of the response to triple therapy in hard-to treat patients.  324 
We predicted that both PIs achieved a high level of antiviral effectiveness in blocking viral 325 
production that was higher than 97.9% in all patients. However telaprevir had a higher 326 
intrinsic potency than boceprevir, as measured by EC50 (P=0.008 after correcting for small 327 
sample size), leading to a significantly higher level of antiviral effectiveness than boceprevir 328 
(İsstelaprevir = 99.8% vs İssboceprevir = 99.0%, P=0.002) i.e. a 5-fold difference in the viral 329 
production under treatment. Importantly the difference in EC50 was obtained despite the fact 330 
that the study was not randomized and that patients who received telaprevir had less favorable 331 
baseline characteristics than those who received boceprevir with higher baseline VL (6.43 332 
log10 IU/ml vs 5.52 log10 IU/ml, respectively, P<10
-4
) and a higher proportion of null 333 
responder to previous bitherapy (4/9 vs 1/6). 334 
The comparison of drug’s antiviral effectiveness should be taken with caution because of 335 
small sample size, the absence of randomization, and the fact that only trough concentrations 336 
were used to estimate the EC50 of PI which may lead to underestimation. Yet these results 337 
demonstrate for the first time a significant association between serum exposure to PI agents 338 
and the antiviral effectiveness achieved. To confirm the significance of this association we 339 
fitted HCV RNA data to a simplified model where drug exposure was not taken into account 340 
(37). As compared to this model, we found that the PK-VK model both improved the fitting 341 
criterion (BIC decreases from 181.3 to 176.3, i.e. an improvement of 5 points which is 342 
regarded as positive evidence) and reduced the between-patient parameter variability by 26% 343 
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(ωEC50PI from 0.85 to 0.61), thus demonstrating that serum PK is an important predictor of the 344 
antiviral effectiveness of triple therapy.  345 
Our estimate that telaprevir achieves an antiviral effectiveness of 99.8% is largely similar to 346 
the one found in naïve patients (15), suggesting that compensated cirrhosis does not affect the 347 
maximal antiviral effectiveness of telaprevir. Whether this is also true for boceprevir is not 348 
known as to our knowledge there is no published viral kinetic modeling study evaluating the 349 
in vivo antiviral effectiveness of boceprevir. 350 
In contrast to the high effectiveness achieved by both PIs, Peg-IFN was found to have a 351 
modest contribution in blocking viral production, with a mean value of 43.4%. Of note 352 
including the patient who did not receive Peg-IFN in our analysis allow us to add information 353 
on telaprevir antiviral effectiveness. Further RBV exposure had no significant contribution on 354 
the early viral kinetics. Together these results indicate that Peg-IFN and RBV have a minimal 355 
contribution on the early virologic response, at least on this population of previous non-356 
responders to a Peg-IFN/RBV therapy.  357 
In order to achieve a rapid viral decline, it is important to achieve not only a high level of 358 
effectiveness but also a rapid second phase of viral decline. Here the latter was rather slow in 359 
both treatment groups compared to what had been than found in telaprevir treated patients, 360 
and this was attributed in our model to a low loss rate of infected cells, į, about three times 361 
smaller than in non-cirrhotic naive-patients (į of 0.18 day-1 vs 0.60 day-1) (15, 16). Those 362 
lower values may encompass several factors, such a lower penetration of PIs into infected 363 
cells in a highly scarced liver. Because the loss rate of infected cells is strongly related to the 364 
treatment duration needed to achieve SVR (15), our results suggest that the time to achieve 365 
SVR in this population could be longer than what had been predicted from clinical trials (15). 366 
Consistent with this prediction, the relapse rate in the CUPIC trial was equal to 41% in both 367 
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treatment groups (13), i.e., much higher than what reported in treatment experienced patients 368 
phase 3 clinical trials (12% to 27%) (9, 11, 22). 369 
Regarding the use of early viral kinetic parameters for treatment prediction, we found that į 370 
was higher in patients that subsequently achieved SVR (median įSVR = 0.27 day-1 vs median 371 
įnon-SVR = 0.14 day-1, P=0.03) suggesting that į could be a relevant predictor of the outcome of 372 
triple therapy, as it was the case for Peg-IFN/RBV bitherapy (38). In contrast there was no 373 
significant relationship between antiviral effectiveness of PIs on SVR (Fig. 6A). This absence 374 
of relationship is consistent with the hypothesis that in order to achieve SVR, it is necessary 375 
not only to have a high antiviral effectiveness at treatment initiation, when the viral 376 
population is predominantly wild-type and drug-sensitive, but also at later times, when the 377 
viral population is predominantly resistant to PI agents (39, 40). The fact that neither Peg-IFN 378 
effectiveness nor RBV were associated with SVR is more surprising, as one would expect 379 
these agents to be equally active against wild-type and resistant virus. However our patient 380 
population was both treatment experienced and cirrhotic, two major causes of insensitivity to 381 
Peg-IFN/RBV.  382 
Clearly the main limitation of this study was its small size. In a previous study we evaluated 383 
by simulation the power to detect a difference of antiviral effectiveness between two 384 
treatment groups for a variety of designs (34). With a design comparable to the present study, 385 
i.e., 10 patients per group, 7 VL per patient and an antiviral effectiveness of 99% vs 99.9%, 386 
the power to detect this difference was 100% with the same statistical method that we used in 387 
this analysis. Yet, further studies on larger populations will still be needed to estimate more 388 
precisely the exposure-effect relationship (Fig. 4) and other kinetic parameters involved on 389 
the long-term virologic response. A second limitation is that only trough pre-dose drug 390 
concentrations were collected and modeled. Thus Css is the steady-state Ctrough. Moreover no 391 
information was collected on treatment adherence. The data analysis did not show any signal 392 
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of lack of adherence such as viral oscillations, which indicates that missed doses, if they 393 
occurred, did not have a major effect on the observed kinetic of decline. Here we considered 394 
that concentrations of PIs were constant over time. Detailed pharmacokinetic analysis showed 395 
that steady state of residual concentrations is attained after two days of treatment (41). As 396 
explained in details in Guedj et al. (42), the fact that we neglected this initial build up may 397 
explain why our estimate of the viral clearance rate, c, was lower than previously found in 398 
treatment naïve patients (15). Further the lack of information on the time of Peg-IFN injection 399 
also precluded a precise characterization between Peg-IFN exposure and the virological 400 
response. The fact that we used rather empirical models is less problematic for RBV, whose 401 
long elimination half-life resulting in a slow increase over time could be well characterized 402 
here (27). Moreover, as mentioned previously, in order to achieve SVR, it is important for 403 
drugs to achieve a higher effectiveness against PI-resistant virus. Because no sequencing was 404 
done here, we focused only the early virological response where presumably the virus is 405 
predominantly drug-sensitive. In order to estimate PI effectiveness against resistant virus it 406 
would be needed to quantify and follow the proportion of resistant virus over time, as early as 407 
possible, for instance using pyrosequencing (43).  408 
A greater proportion of patients that received boceprevir were genotype 1a relative to those 409 
that received telaprevir (P=0.04). It has been well established that subgenotype is an important 410 
predictor of the response to treatment and for instance the fact that telaprevir has a higher 411 
genetic barrier to resistance with genotype 1b than 1a (36) may explain why genotype non-1a 412 
patients were preferentially treated with telaprevir than boceprevir. However the effect of 413 
subgenotype on the early viral kinetics, where most of the virus is drug-sensitive is unknown, 414 
and has never been investigated as far as we know. In our study no significant effect of 415 
subgenotype on any of the parameters (c, į, EC50PI) was found. 416 
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The effect of RBV was analyzed using serum drug concentrations. Some authors preferably 417 
used erythrocyte RBV concentration (44), which was not measured in the present study. 418 
However a significant relationship was shown between erythrocyte RBV concentrations and 419 
serum concentrations (45), suggesting that serum RBV can be used for the assessment of early 420 
and sustained virological responses (46, 47).  421 
To summarize this study provides the first characterization of the relationship between drug 422 
concentrations involved in triple therapy and early HCV viral kinetics treated with telaprevir 423 
or boceprevir. We found that median values of antiviral effectiveness for telaprevir was 424 
similar to what had been found in treatment naïve patients and significantly larger than in 425 
boceprevir treated patients. In all patients the second phase of viral decline was slow and may 426 
explain the high relapse rate observed in the ANRS-CO20-CUPIC cohort. This suggests that, 427 
notwithstanding safety issues, longer treatment duration could improve the treatment efficacy 428 
and lead to a higher SVR rate. Lastly the antiviral effectiveness of Peg-IFN was modest (less 429 
than 50%) suggesting that cirrhotic treatment experienced-patients may particularly benefit 430 
from upcoming IFN-free treatment. Our approach, which shows the importance of PK data to 431 
disentangle the effects of drug combination and to understand the variability in the virological 432 
response, is not specific to triple therapy and could also be used to optimize future IFN-free 433 
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Figure legends 628 
 629 
Fig. 1: Observed concentrations over time. 630 
(a) telaprevir in 9 patients (black, µmol/ml) and boceprevir in 6 six patients (grey, µmol/ml); 631 
(b) Peg-IFN in telaprevir group (black, ng/ml) and in boceprevir group (grey, ng/ml); (c) RBV 632 
in telaprevir group (black, ng/ml) and in boceprevir group (grey, ng/ml). Patients who 633 
received a boceprevir-based therapy had only two blood samples during the lead-in phase at 634 
baseline and week 2. 635 
 636 
Fig. 2: Individual fits of the viral decline (log10 IU/ml). 637 
Nine patients in telaprevir group (black curve) and 6 patients in boceprevir group (grey 638 
curve). Black crosses represent the observed viral load and grey stars represent the viral load 639 
under the limit of detection. 640 
 641 
Fig. 3. Goodness-of-fit of the viral kinetic-pharmacokinetic model 642 
Residuals (weighted residuals calculated using individual predictions: IWRES and normalized 643 
prediction distribution errors: NPDE) versus time and versus predictions plots. Residuals 644 
seem to distribute homogenously around 0. 645 
Observed viral load are plotted as black crosses and viral load under the limit of detection as 646 
grey stars. 647 
 648 
Fig. 4. Relationship between predicted trough concentration at steady state (Css) and 649 
predicted antiviral effectivenesses (εss). 650 
(a) for the protease inhibitor (telaprevir in black and boceprevir in grey, µmol/l); (b) for Peg-651 
IFN (Peg-IFN-α2a in black and Peg-IFN-α2b in grey, ng/ml). The lines denote the predictions 652 
28 
 
with the mean antiviral effectiveness and the dotted lines denote 95% confidence interval 653 
computed with the standard errors predicted by the Fisher Information Matrix. 654 
 655 
Fig. 5: Relationship between long term virological response (SVR) and parameters 656 
estimated by the viral kinetic-pharmacokinetic model. 657 
(a) predicted antiviral effectivenesses (İss) of PIs; (b) predicted antiviral effectivenesses (İss) 658 



















Age (years), median [min-max]  55 [49-59] 53 [44-64] 55 [44-64] 
Males, n (%)  8 (89) 4 (67) 12 (80) 
HCV RNA (log10 IU/ml), median [min-max] 6.5 [6.0-6.8]  5.4 [4.9-6.6]  6.2 [4.9-6.8]  
HCV genotype, n (%): 
     1a 










IL28B genotype (rs12979860), n (%): 
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     C/T 
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Table 2. Individual predicted trough concentrations at steady state (Css) 4 
 
n median [min; max] 
Css
telaprevir 
(µmol/l) 9 3.77 [2.68; 5.98] 
Css
boceprevir 
(µmol/l) 6 3.92 [3.22; 7.64] 
Css
Peg-IFN-α2a
 (ng/ml) 11 89.6 [52.8; 110.4] 
Css
Peg-IFN-α2b
 (ng/ml) 3 55.4 [55.3; 57.9] 
Css
RBV 




Table 3. Parameter estimates and relative standard errors (RSE) 6 
 
Estimate RSE (%) 
V0
telaprevir 
(log10 IU/ml) 6.43 2 
V0
boceprevir 
(log10 IU/ml) 5.52 3 
c (day
-1
) 3.98 12 
δ (day-1)  0.18 11 
EC50
Peg-IFN
 (ng/ml) 106 40 
EC50
telaprevir
 (µmol/l) 0.009 30 
EC50
boceprevir
 (µmol/l) 0.04 43 
ωV0  0.07 20 
ωc  0.47 19 
ωδ  0.42 16 
ωEC50Peg-IFN  0.67 30 
ωEC50PI  0.61 32 
σ  0.27 7 
V0: baseline viral load; c: clearance rate of virus from serum; δ: loss rate of 7 
infected cells; EC50: half maximal effective concentration; ω: inter-8 
individual variability; σ: standard deviation of residual error; RSE: relative 9 
standard errors of parameter estimates, PI: protease inhibitor.  10 
